THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS

被引：0
作者：
Hou, J. [1 ]
Du, X. [2 ]
Jin, J. [3 ]
Cai, Z. [3 ]
Chen, F. [4 ]
Zhou, D. [5 ]
Yu, L. [6 ]
Ke, X. [7 ]
Li, X. [8 ]
Wu, D. [9 ]
Meng, F. [10 ]
Ai, H. [11 ]
Zhang, J. [12 ]
Chen, N. [12 ]
Mei, J. [12 ]
Wang, J. [13 ]
机构：
[1] Shanghai Changzheng Hosp, Shanghai, Peoples R China
[2] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[4] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[5] Beijing Union Med Coll Hosp, Beijing, Peoples R China
[6] 301 Mil Hosp, Beijing, Peoples R China
[7] Peking Univ, Hosp 3, Beijing, Peoples R China
[8] Shanghai Sixth Peoples Hosp, Shanghai, Peoples R China
[9] Suzhou Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[11] 307 PLA Hosp, Beijing, Peoples R China
[12] Celgene Corporat, Summit, NJ USA
[13] Changhai Hosp, Shanghai, Peoples R China
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P813
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [31] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [32] Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM)
    Raschko, Martha
    Markovina, Stephanie
    Miyamoto, Shigeki
    Longo, Walter
    Williams, Eliot
    McFarland, Thomas
    Wemdli, Jae
    Wagner, Elisabeth
    Juckett, Mark
    Callander, Natalie
    BLOOD, 2007, 110 (11) : 355A - 356A
  • [33] Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM)
    Bensinger, W.
    Wang, M.
    Orlowski, R. Z.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrall, N. Y.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] PX-171-006, A PHASE IB DOSE-ESCALATION STUDY OF CARFILZOMIB plus LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Wang, M.
    Bensinger, W.
    Orlowski, R.
    Alsina, M.
    Martin, T.
    Singhal, S.
    Gabrail, N.
    Vallone, M.
    Kauffman, M.
    Niesvizky, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 157
  • [35] A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results
    Richardson, Paul G.
    Jagannath, Sundar
    Moreau, Philippe
    Jakubowiak, Andrzej
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    White, Darrell J.
    Reece, Donna
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Deng, Wei
    Kroog, Glenn
    Singhal, Anil K.
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [36] A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    White, Darrell J.
    Bahlis, Nizar J.
    Venner, Christopher P.
    Schiller, Gary J.
    Gasparetto, Cristina J.
    Sutherland, Heather J.
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Bensinger, William
    Lipe, Brea C.
    Chen, Christine I.
    Del Col, Aldo
    Kauffman, Michael G.
    Shacham, Sharon
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    LeBlanc, Richard
    BLOOD, 2017, 130
  • [37] MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
    Matous, Jeffrey
    Siegel, David S.
    Lonial, Sagar
    Harvey, R. Donald
    Kasserra, Claudia
    Li, Yan
    Chen, Min
    Doerr, Thomas
    Sternas, Lars
    Zaki, Mohamed H.
    Jacques, Christian
    Shah, Jatin J.
    BLOOD, 2014, 124 (21)
  • [38] LENALIDOMIDE PLUS HIGH-DOSE VERSUS LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
    Kupas, K.
    Kaspar, I.
    Baecke, V.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 514 - 515
  • [39] A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
    Reu, Frederic J.
    Grabowski, Dale
    Mahfouz, Reda Z.
    Lazarus, Hillard M.
    Dean, Robert M.
    Faiman, Beth
    Reed, Janice
    Karam, Mary Ann
    Hamilton, Kimberly
    Fada, Sherry
    Kalaycio, Matt E.
    Valent, Jason Neil
    Samaras, Christy Joy
    Sobecks, Ronald M.
    McCowen, Linda
    Elberson, Jamie
    Liu, Hien
    Saunthararajah, Yogen
    Chew, Yap
    Smith, Mitchell R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    DeMarco, Dena
    Zhang, Jingshan
    Mei, Jay
    Hou, Jian
    BMC CANCER, 2016, 16
12345